

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C.20231  
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 28 February 2000 (28.02.00)	
International application No. PCT/US98/25964	Applicant's or agent's file reference 609.1PC
International filing date (day/month/year) 08 December 1998 (08.12.98)	Priority date (day/month/year) 08 December 1997 (08.12.97)
Applicant LEE, Taekyu et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

07 July 1999 (07.07.99)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Juan Cruz
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C07K5/02		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	C07K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with Indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
P, X	EP, A, 361341 (MOLECULAR THERAPEUTICS) 04 April 1990 see the whole document ---	1-6
P, X	EP, A, 346847 (HOFFMANN-LA ROCHE) 20 December 1989 see claim 1 ---	1-7
<p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
11 MARCH 1991	25. 03. 91	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	M. PEIS M. Per3	

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9007059  
SA 42756

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20/03/91

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-361341	04-04-90	AU-A- 4230889 JP-A- 2191243	16-08-90 27-07-90
EP-A-346847	20-12-89	AU-A- 3613089 JP-A- 2042048	14-12-89 13-02-90

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b> <b>C07K 5/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 91/08221</b> <b>(43) International Publication Date:</b> 13 June 1991 (13.06.91)
<b>(21) International Application Number:</b> PCT/US90/07059 <b>(22) International Filing Date:</b> 3 December 1990 (03.12.90) <b>(30) Priority data:</b> 445,070 4 December 1989 (04.12.89) US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 445,070 (CIP) Filed on 4 December 1989 (04.12.89) <b>(71) Applicant (for all designated States except US):</b> WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 North Walnut Street, Madison, WI 53705 (US).		<b>(71)(72) Applicant and Inventor:</b> MARSHALL, Garland, R. [US/US]; 85 Arundel Place, Clayton, MO 63105 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> RICH, Daniel, H. [US/US]; 1852 Summit Avenue, Madison, WI 53705 (US). GREEN, Jeremy [US/US]; 8783 C Lemode Court, Indianapolis, IN 46248 (US). SUN, Chongqing [CN/US]; 803 Eagle Heights, Apt. A., Madison, WI 53705 (US). <b>(74) Agents:</b> SCHWARTZ, Carl, R. et al.; Quarles & Brady, 411 East Wisconsin Avenue, Milwaukee, WI 53202 (US). <b>(81) Designated States:</b> AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> PEPTIDE INHIBITORS OF HIV PROTEASE		
<b>(57) Abstract</b>  The invention provides HIV protease inhibitors which are potential drugs for HIV infected patients or cells. Preferably, peptides are provided that have an amino alcohol core that mimics a Phe-Pro and/or Leu-Pro binding site for the protease. The core is preferably ringed by at least three amino acids. In one form, an N-terminal cap is positioned adjacent to an Asn residue.  <div style="text-align: right;"><i>Check</i> <i>JL</i> <i>1/2-2000</i></div>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CI	Côte d'Ivoire	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

-1-

PEPTIDE INHIBITORS OF HIV PROTEASE

This invention was made with U.S. government support awarded by the National Institutes Of Health (NIH) Grant Nos: GM40092, DK20100, AI27302 The U.S. government has  
5 certain rights in this invention.

Technical Field

This invention relates to uses of a modified peptide as an inhibitor of HIV protease. More particularly, it relates to incorporating amino-alcohol variants of the  
10 protease's preferred binding site in a special peptide backbone to preferentially bind and occupy the protease.

Background Art

An important problem facing medical science is the development of drugs for those already infected by HIV.  
15 Inhibition of viral proteases as an approach to antiviral therapy has been demonstrated with another virus by Korant et al., 32 J. Cell. Biochem. 91-95 (1986), who showed that an inhibitor of cysteine proteases, cystatin, inhibited replication of poliovirus in tissue culture. Also,  
20 Oroszlan, Abstract AIDS Symposium (June 1987) demonstrated inhibition by p pstatin of processing of gag-pol poly


-2-

protein by purified HIV protease in vitro and in tissue culture in the presence of DMSO. The disclosure of the above articles and of all other articles referred to herein are incorporated by reference as if fully set forth  
5 herein.

The goals of any drug to be used in humans are that the drug should have high potency, high specificity, few side effects, stability, and reasonable costs of manufacture. Unfortunately, to date no drug for AIDS  
10 inhibition treatment has satisfactorily met all of these criteria.

#### Disclosure Of The Invention

We identify herein peptide variants which preferentially bind to HIV protease so as to inhibit its  
15 activity. In one embodiment, the present invention provides a peptide having the moiety:



where R<sub>1</sub> is selected from the group consisting of isobutyl, benzyl, cyclohexylmethyl, and other arylalkyl or alkyl moieties with less than twelve carbons; and where R<sub>2</sub>  
25 and R<sub>3</sub> each has at least one amino acid residue, and at least one of R<sub>2</sub> or R<sub>3</sub> has at least two amino acid residues.

In another aspect, R<sub>2</sub> is also linked to the following

-3-

moiety:



5

Preferably, R<sub>2</sub> and R<sub>3</sub> are residues of one or more of the twenty amino acids commonly found in proteins or one of the other naturally occurring amino acids. See A. Lenhniger, Biochemistry, p.69-72 (1970). In an especially preferred form, R<sub>2</sub> contains an asparagine residue. Also, R<sub>1</sub> is preferably a side chain found on a naturally occurring amino acid.

The objects of the invention therefore include providing compositions of the above kind that are relatively inexpensive to produce and will inhibit HIV protease. These and still other objects and advantages of the present invention will be apparent from the description which follows. The following embodiments do not represent the full scope of the invention. Rather, the invention may be employed in other embodiments. Reference is therefore to be made to the claims herein for interpreting the scope of the present invention.

#### Brief Description Of The Drawings

Fig. 1 depicts the synthesis of half of a peptide of the leucine amino alcohol type;

Fig. 2 depicts the synthesis of the other half of the molecule;

Fig. 3 depicts the synthesis of three final products;

Fig. 4 is similar to Fig. 1, but depicts phenyl variants;

Fig. 5 is similar to Fig. 3, but depicts phenyl variants;



-4-

Fig. 6 depicts another system for protecting one end of the final product;

Fig. 7 depicts the synthesis of one-half of another peptide;

5 Fig. 8 depicts the synthesis of two variants of the other half of the peptide;

Fig. 9 depicts two coupling reactions; and

Fig. 10 depicts two N-terminal caps.

### Best Modes For Carrying Out The Invention

10

### General Procedures

In the discussion below, the following abbreviations are used: AcOH - acetic acid; Boc - t-butoxycarbonyl; BuOH - butanol; DCM - dichloromethane; DMF - N,N-dimethylformamide; DMSO - dimethylsulphoxide; EDCI - N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; HOBt - 1-hydroxybenzotriazole; MeOH - methanol; NMM - N-methylmorpholine; Z - benzyloxycarbonyl.

15 A: Isobutyl chloroformate mediated coupling reactions:  
To a cold (-25°C) solution of N $\alpha$ -protected amino acid (100 mmol) in dry dichloromethane (200-400 mL) is added N-methylmorpholine (100 mmol) followed by careful addition of isobutyl chloroformate (100 mmol) maintaining the temperature of the solution between -15 and -25°C. The solution is stirred at -25°C for a further 20 minutes,  
20 then a solution of amino acid or peptide ester hydrohalide or toluenesulphonate salt (100 mmol) in DMF and/or DCM is added followed by addition of NMM (100 mmol). The reaction is stirred for 1 hour at -20°C and for a further 1-3 hours at room temperature. The solvent is removed in vacuo and the residue taken up in ethyl acetate and washed  
25  
30

-5-

with saturated  $\text{NaHCO}_3$  (x2), 5% citric acid solution, saturated  $\text{NaHCO}_3$ , water and brine, and dried over  $\text{MgSO}_4$ . Evaporation of the solvent yields a solid which is recrystallized from a suitable solvent combination.

5 B: EDCI/HOBt mediated peptide couplings:

Boc amino acid and HOBt (1.5 equivalent) are dissolved in dry DMF (2-5 mL per mmol) and cooled to  $0^\circ\text{C}$ . EDCI (1.1 equivalent) is added and the solution stirred for 30-40 minutes. A solution of amino acid or peptide,  
10 ester or chloromethylketone, amine hydrochloride (0.9 equivalent) in DMF (1-5 mL per mmol) is added, followed by NMM (0.9 equivalent). The reaction is stirred for 1-2 hours at  $0^\circ\text{C}$  and overnight at room temperature. The reaction is worked up by direct precipitation of the crude  
15 product from a concentrated DMF solution by careful addition of a large volume of 60% saturated  $\text{NaHCO}_3$ . The precipitate is collected by filtration over a hardened filter paper (Whatman No. 50 or 54), and the solid washed thoroughly with saturated  $\text{NaHCO}_3$  (200-500 mL), water (200-  
20 500 mL), 5% citric acid solution (200-500 mL), and water (200-500 mL). The product is dried in vacuo, redissolved in DMF, filtered through a glass wool plug and reprecipitated by addition of water. Again the product is filtered, washed with water, and dried.

25 C: Cleavage of Boc protecting group with 4N HCl in dioxane:

The Boc-protected peptide or amino acid derivative is dissolved in 4N HCl in dioxane (Pierce) (6-40 equivalents) and stirred at room temperature for 30-60 minutes, the  
30 course of reaction being monitored by thin layer chromatography. Once complete, the solution is evaporated to dryness at  $<30^\circ\text{C}$  and the residue evaporated from anhydrous ether (x3) to remove traces of HCl. The crude product is dried in vacuo in a desiccator over NaOH  
35 pell ts overnight and is used without further purification or characterization.

D: Preparation of amino acid diazomethyl ketones:

N $\alpha$ -Protected amino acid (50 mmol) is dissolved in dry THF (100 mL) and cooled to -25°C. NMM (50 mmol) is added, followed by isobutylchloroformate (50 mmol), with the temperature being maintained at -25°C during addition. After stirring for 5 minutes anhydrous ether (100 mL) is added while simultaneously cooling the solution to -70°C. The cold solution is quickly filtered under a blanket of N<sub>2</sub> and the cold filtrate treated with a solution containing approximately 70 mmol of diazomethane in ether (250 ml). The reaction is allowed to gradually warm up to room temperature and excess diazomethane is removed by purging the solution with a stream of N<sub>2</sub> for 15-30 minutes. The solution is evaporated to dryness and the residue taken up in ether (200 mL), and washed with saturated NaHCO<sub>3</sub> and brine, and dried over MgSO<sub>4</sub>. The product may be crystallized from ether-hexane or hexane.

E: Conversion of diazomethylketones to halomethylketones:

The amino acid diazomethylketone is dissolved in anhydrous dioxane. After slow addition of the first equivalent of HCl in dioxane is complete (slow addition is necessitated by the rapid evolution of nitrogen), a further 6-10 equivalents is added and the cooling bath removed. The reaction is stirred at room temperature for 1 hour and the product precipitated by addition of ether. The product is filtered, washed with copious amounts of ether, and dried in vacuo over NaOH pellets. Prolonged storage of these compounds results in significant colouration and decomposition.

F: Acetylation of peptides:

A solution of the peptide amine hydrochloride in dry DMF (10-20 mL/g) is cooled to 0°C in an ice-water bath and neutralized with triethylamine (2.1-2.5 equivalents). A solution of acetyl chloride in DCM (0.3-1.8 M) is then added dropwise and the reaction left to stir for 1 hour at

-7-

0°C, and for a further 1 hour at room temperature. The solution is then concentrated to a small volume under high vacuum, and water is added to precipitate the acetylated peptide, which is collected by filtration, and  
5 washed with water, before drying in vacuo over NaOH pellets.

G: Preparation of Aminoketones:

N $\alpha$ -Protected peptide chloromethylketone derivatives (1.0 mmol) are dissolved in DMF (4-7 mL per mmol) and NaI  
10 (1.1 mmol) added and the mixture stirred for 15 minutes. The peptide ester toluenesulphonate salt (1.1 mmol) in DMF (2-5 mL per mmol) is added followed by NaHCO<sub>3</sub> (2.1 mmol) and the reaction left to stir for 12-18 hours at room temperature. Upon complete reaction, the solution is  
15 diluted with ethyl acetate (50-70 ml), and washed with water (1N KHSO<sub>4</sub> may also be used, though the potential solubility of an amine-containing peptide must be considered). The aqueous layer is extracted with ethyl acetate (x2) and the combined extracts washed with water  
20 and brine before drying over Na<sub>2</sub>SO<sub>4</sub>. The product thus obtained is of good purity, though silica gel chromatography carried out to remove trace impurities contributes to epimerisation at the chiral centre  $\alpha$  to the ketone carbonyl.

25 H. Reduction of aminoketones to aminoalcohols:

The crude aminoketone (1.0 mmol) is taken up in anhydrous MeOH (10 mL), cooled to 0°C and treated with NaBH<sub>4</sub> (2.5 equiv.) in a single portion. The course of  
30 reaction is monitored by thin layer chromatography, and addition of extra NaBH<sub>4</sub> is occasionally necessary. Upon completion of reduction, the solution is treated with ethyl acetate (50 mL) and water (50 mL). The aqueous phase is extracted with ethyl acetate (x2) and the combined extracts washed with water and brine, and dried  
35 over Na<sub>2</sub>SO<sub>4</sub>. The product is purified by silica gel chromatography using a gradient of methanol in chloroform

-8-

for optimal separations.

I. Hydrogenolytic deprotection of final products:

5 The amino alcohol containing peptides (50  $\mu$ mol) are dissolved in 90% acetic acid (3.5 mL) and 20% palladium hydroxide on charcoal (Pearlman's catalyst) is added under an N<sub>2</sub> atmosphere. Deprotection is achieved by passage of H<sub>2</sub> as a steady stream through the solution for 3-4 hours. The catalyst is removed by filtration through pre-washed and swollen Celite, and the filtrate concentrated in vacuo 10 to approximately 1 mL total volume. The solution is diluted with water (20 ml), washed with chloroform (x3), and re-concentrated to 5-8 mL total volume. The solution is filtered through a glass wool plug, and lyophilized to yield the final product peptide as a fine colourless 15 powder.

Examples

1.1 (3S)-t-Butoxycarbonylamino-1-diazo-5-methyl-2-hexanone, (BocLeuCHN<sub>2</sub>). Compound 1.1 was prepared according to general procedure D from Boc leucine monohydrate (13.89 g, 55.7 mmol). The product was crystallized from ether-hexane. 20

1.2 (3S)-Amino-1-chloro-5-methyl-2-hexanone hydrochloride, (Cl-H<sub>2</sub>+LeuCH<sub>2</sub>Cl). Compound 1.2 was prepared from Compound 1.1 (5.46 g, 21.4 mmol) in ether (21 mL), 25 and a solution of 4N HCl in dioxane (25 mL, 100 mmol) as described in general procedure E.

1.3 (3S)-(N-t-Butoxycarbonylasparaginy)amino-1-chloro-5-methyl-2-hexanone, (BocAsnLeuCH<sub>2</sub>Cl). Compound 1.3 was prepared from Boc asparagine (3.45 g, 14.9 mmol) 30 and Compound 1.2 (2.70 g, 13.5 mmol) according to general procedure B.

-9-

1.4 (3S)-(N-t-butoxycarbonylleucinylasparaginyl)amino-1-chloro-5-methyl-2-hexanon,  
(BocLeuAsnLeuCH<sub>2</sub>Cl). Compound 1.4 was prepared by  
deprotection of Compound 1.3 (5.78 g, 15.3 mmol) according  
to general procedure C, and coupling with Boc leucine  
monohydrate (4.16 g, 16.7 mmol) according to general  
procedure B.

1.5 (3S)-N-Acetylleucinylasparaginyl)amino-1-chloro-5-methyl-2-hexanone,  
(AcLeuAsnLeuCH<sub>2</sub>Cl). Compound 1.5 was  
prepared by deprotection of Compound 1.4 (0.99 g,  
2.02 mmol) according to general procedure C, followed by  
acetylation by general procedure F.

1.6 (3S)-N-t-Butoxycarbonyl-O-benzylserinylleucinylasparaginyl)-amino-1-chloro-5-methyl-2-hexanone,  
(BocSer(Bzl)LeuAsnLeuCH<sub>2</sub>Cl). Compound 1.6 was prepared by  
deprotection of Compound 1.4 (1.14 g, 2.32 mmol) according  
to general procedure C, and coupling with Boc serine  
benzyl ether (0.77 g, 2.61 mmol) according to general  
procedure B.

1.7 (3S)-N-Acetyl-O-benzylserinylleucinylasparaginyl)-amino-1-chloro-5-methyl-2-hexanone,  
(AcSer(Bzl)LeuAsnLeuCH<sub>2</sub>Cl). Compound 1.7 was prepared by  
deprotection of Compound 1.6 (643 mg, 0.96 mmol) according  
to general procedure C, followed by acetylation according  
to general procedure F.

2.1 N $\alpha$ -t-Butoxycarbonylisoleucylvaline methyl ester,  
(BocIleValOMe). Compound 2.1 was prepared from valine  
methyl ester hydrochloride (19.99 g, 119 mmol) and Boc  
isoleucine hemihydrate (26.05 g, 108 mmol) according to  
general procedure A, and recrystallized from ethyl  
acetate-hexane.

2.2 N-Benzylloxycarbonylprolylisoleucylvaline methyl ester,  
(ZProIleValOMe). Compound 2.2 was prepared from  
Compound 2.1 (14.00 g, 40.6 mmol) by deprotection accord-  
ing to general procedur C, followed by coupling with 2-  
prolin (10.09 g, 40.5 mmol) according to general

-10-

procedure A. The product was recrystallized from ethyl acetate-hexane.

2.3 Prolylisoleucylvaline methyl ester tosylate, (TosO-H<sub>2</sub>+ProIleValOMe). Compound 2.3 (5.11 g, 10.7 mmol) was deprotected by catalytic hydrogenation as follows. The protected tripeptide was dissolved in methanol (130 mL) together with p-toluenesulphonic acid (2.17 g, 11.4 mmol), and 10% palladium on charcoal (0.5 g) was added under an N<sub>2</sub> atmosphere. Hydrogen gas was bubbled through the mixture for 16 hours. Then the solution was filtered through celite to remove the catalyst, and evaporated to dryness to reveal the tripeptide as a foam. The excess p-toluenesulphonic acid was removed by trituration with ether and the tripeptide salt stored sealed under N<sub>2</sub> as a hygroscopic glass.

3.1 (2RS,3S)-3-(N-Acetyl-leucinyllasparaginyll)-amino-2-hydroxy-5-methyl-1-(N-prolylisoleucylvaline methyl ester)-hexane, (AcLeuAsnLeu\*(CHOHCH<sub>2</sub>N)ProIleValOMe). Compound 3.1 was prepared from Compound 1.5 (133 mg, 308 μmol) and Compound 2.3 (235 mg, 457 μmol) in DMF (4 mL) as described in general procedure G. The crude product was reduced without further purification using NaBH<sub>4</sub> (26 mg, 679 μmol) as described in general procedure H. The crude product was purified by chromatography on silica gel, using a gradient of 5-11% MeOH in CHCl<sub>3</sub>.

3.2 (2RS,3S)-3-(N-Acetyl-O-benzylserinyll-leucinyllasparaginyll)-amino-2-hydroxy-5-methyl-1-(N-prolylisoleucylvaline methyl ester)-hexane, (AcSer(Bzl)LeuAsnLeu\*(CHOHCH<sub>2</sub>N)ProIleValOMe). Compound 3.2 was prepared from Compound 1.7 (160 mg, 262 μmol) and Compound 2.3 (201 mg, 392 μmol) in DMF (4.5 mL) as described in general procedure G. The crude product was reduced without further purification as described in general procedure H, and purified by chromatography on silica gel, using a gradient of 5-11% MeOH in CHCl<sub>3</sub>.

3.3 (2RS,3S)-3-(N-Acetylserinylleucinylasparaginyl)-  
amino-2-hydroxy-5-methyl-1-(N-propylisoleucylvaline methyl  
ester)-hexane, (AcSerLeuAsnLeu\* (CHOHCH<sub>2</sub>N)  
ProIleValOMe.AcOH). Compound 3.2 was prepared from  
5 Compound 3.2 (46 mg, 50.5  $\mu$ mol) by hydrogenation over  
palladium hydroxide on charcoal (16 mg) in 90% acetic acid  
as described in general procedure I.

4.1 (3S)-t-Butoxycarbonylamino-1-diazo-4-phenyl-2-  
butanone, (BocPheCHN<sub>2</sub>). Compound 4.1 was prepared  
10 according to general procedure D from Boc phenylalanine  
(13.28 g, 50.0 mmol). The product was crystallized from  
ether-hexane.

4.2 (3S)-Amino-1-chloro-4-phenyl-2-butanone  
hydrochloride, (Cl-H<sub>2</sub>+PheCH<sub>2</sub>Cl). Compound 4.2 was prepared  
15 from Compound 4.1 (10.01 g, 34.6 mmol) in dioxane (25 mL),  
and a solution of 4N HCl in dioxane (50 mL, 200 mmol) as  
described in general procedure E.

4.3 (3S)-(N-t-Butoxycarbonylasparaginyl)amino-1-  
chloro-4-phenyl-2-butanone, (BocAsnPheCH<sub>2</sub>Cl). Compound  
20 4.3 was prepared from Compound 4.2 (7.04 g, 30.1 mmol) and  
Boc asparagine (7.66 g, 33.0 mmol) in DMF (100 mL), as  
described in general procedure B.

4.4 (3S)-N-t-Butoxycarbonylleucinylas-  
paraginyl)amino-1-chloro-4-phenyl-2-butanone,  
25 (BocLeuAsnPheCH<sub>2</sub>Cl). Compound 4.4 was prepared by  
deprotection of Compound 4.3 (9.74 g, 23.7 mmol) according  
to general procedure C, followed by coupling with Boc  
leucine (6.55 g, 26.3 mmol) (monohydrate dried together  
with HOBt hydrate by repeated azeotropic removal of water  
30 from DMF-toluene solution) in DMF (70 mL), as described in  
general procedure B.

4.5 (3S)-(N-Acetylleucinylasparaginyl)amino-1-  
chloro-4-phenyl-2-butanone, (AcLeuAsnPheCH<sub>2</sub>Cl). Compound  
4.5 was prepared by deprotection of Compound 4.4 (213 mg,  
35 0.41 mmol) according to general procedure C, and  
subsequently acetylated according to general procedure F.



4.6 (3S)-(N-t-Butoxycarbonyl-O-benzylserinylleucinylasparaginyl)-amino-1-chloro-4-phenyl-2-butanone, (BocSer(Bzl)LeuAsnPheCH<sub>2</sub>Cl). Compound 4.6 was prepared by deprotection of Compound 4.4 according to  
5 general procedure C, followed by coupling with Boc serine benzyl ether (0.99 g, 1.89 mmol) in DMF (11 mL), as described in general procedure B.

4.7 (3S)-(N-Acetyl-O-benzylserinylleucinylasparaginyl)-amino-1-chloro-4-phenyl-2-butanone, (AcSer(Bzl)LeuAsnPheCH<sub>2</sub>Cl). Compound 4.7 was prepared  
10 from Compound 4.6 (674 mg, 0.96 mmol), by deprotection according to general procedure C, and acetylation according to general procedure F.

5.1 (2RS,3S)-3-(N-Acetylleucinylasparaginyl)-amino-2-hydroxy-4-phenyl-1-(N-prolylisoleucylvaline methyl ester)-butane, AcLeuAsnPhe\*(CHOHCH<sub>2</sub>N)ProIleValOMe.  
15 Compound 5.1 was prepared from Compound 4.5 (149 mg, 319  $\mu$ mol) and Compound 2.3 (247 mg, 481  $\mu$ mol) in DMF (4 mL) as described in general procedure G. The crude product was reduced without further purification using  
20 NaBH<sub>4</sub> (29 mg, 767  $\mu$ mol) as described in general procedure H. The crude product was purified by chromatography on silica gel, using a gradient of 5-11% MeOH in CHCl<sub>3</sub>.

5.2 (2RS,3S)-3-(N-Acetyl-O-benzylserinylleucinylasparaginyl)-amino-2-hydroxy-4-phenyl-1-(N-prolylisoleucylvaline methyl ester)-butane, AcSer(Bzl)LeuAsnPhe\*(CHOHCH<sub>2</sub>N)ProIleValOMe. Compound 5.2 was prepared from  
25 Compound 4.7 (188 mg, 292  $\mu$ mol) and Compound 2.3 (223 mg, 435  $\mu$ mol) in DMF (4.5 mL) as described in general procedure G. The crude product was reduced without further purification using NaBH<sub>4</sub> (28 mg, 733  $\mu$ mol) as described in  
30 general procedure H. The crude product from aqueous work up was dried by azeotropic removal of water to prevent precipitation and purified by chromatography on silica  
35 gel, using a gradient of 5-11% MeOH in CHCl<sub>3</sub>.

-13-

5.3 (2RS,3S)-3-(N-Acetylserinylleucinylasparaginyl)-amino-2-hydroxy-4-phenyl-1-(N-prolylisoleucylvaline methyl ester)-butane, (AcSerLeuAsnPhe\*

5 from Compound 5.2 (36 mg, 37.8  $\mu$ mol) by hydrogenation over palladium hydroxide on charcoal (14 mg) in 90% acetic acid as described in general procedure I.

6.1 (2RS,3S)-3(N-[2-aminobenzoyl]-leucinyl-asparaginyl)-amino-2-hydroxy-4-phenyl-1-(N-prolyl-isoleucyl-valyl methyl ester)-butane. (Abz-Leu-Asn-Phe\*(CHOHCH<sub>2</sub>)Pro-Ile-Val-OMe). A BOC protected variant of Compound 3.1, Compound 3.4, (102 mg) was deprotected with 4N HCl in dioxane (4 ml) as described in general procedure C, and subsequently coupled with 2-aminobenzoic acid (29 mg) using EDCI (42 mg) and HOBt (40 mg) as described in general procedure B (2-aminobenzoic acid was not pre-activated). The product was precipitated from DMF by addition of 60% saturated NaHCO<sub>3</sub>. The precipitate was filtered and the solid washed thoroughly with saturated NaHCO<sub>3</sub> and water. The product was dried in vacuo, and purified by preparative thin layer chromatography on 0.5 mm plates using 10% MeOH in CHCl<sub>3</sub> as eluent.

7.1 (3S)-(N-Benzylloxycarbonylasparaginyl)amino-1-chloro-4-phenyl-2-butanone. (ZAsnPheCH<sub>2</sub>Cl). Compound 7.1 was prepared from Compound 4.2 (0.78g, 3.35mmol) and 2-asparagine (0.94g, 3.53mmol) in DMF (20ml) and DCM (15ml), as described in general procedure B.

8.1 N-t-Butoxycarbonylisoleucylphenylalanine methyl ester. (BocIlePheOMe). Compound 8.1 was prepared from phenylalanine methyl ester hydrochloride (1.72g, 8.00mmol) and Boc-isoleucine hemihydrate (1.93g, 8.00mmol) according to general procedure A, and recrystallized from ethyl acetate-hexane.

8.2 N-t-Butoxycarbonylprolylisoleucylphenylalanine methyl ester. (BocProIlePheOMe). Compound 8.2 was prepared from Compound 8.1 (1.00g, 2.55mmol) by

-14-

deprotection according to general procedure C followed by coupling with Boc-proline (0.576g, 2.675mmol) as follows: Boc-proline and HOBt (0.568g, 4.20mmol) were dissolved in DCM (15ml) and cooled to 0°C. EDC1 (0.513g, 2.675mmol) was added and the solution stirred for 30 min. The deprotected Compound 8.1 in DMF (3ml) was added, followed by NMM (0.31ml, 2.80mmol). The reaction was stirred for 10-12 hours at room temperature. The reaction mixture was diluted with ethyl acetate (50ml), washed with saturated NaHCO<sub>3</sub> (15ml), 5% citric acid solution (15ml), brine (25ml) and dried over MgSO<sub>4</sub>. The concentrated product was purified by silica gel chromatography with 50% ethyl acetate in hexane.

8.3 N-t-Butoxycarbonylisoleucyl-3-(2-naphthyl)alanine methyl ester (BocIle-(2-Nap)AlaOMe).  
Compound 8.3 was prepared from 3-(2-naphthyl)alanine methyl ester hydrochloride (0.616g, 2.32mmol) and Boc-isoleucine hemihydrate (0.614g, 2.55mmol) according to the procedure described for Compound 8.2.

8.4 N-t-Butoxycarbonylprolylisoleucyl-3-(2-naphthyl)alanine methyl ester. (BocProIle-(2-Nap)AlaOMe).  
Compound 8.4 was prepared from Compound 8.3 (0.75g, 1.69mmol) by deprotection according to general procedure C, followed by coupling with Boc-proline (0.39g, 1.78mmol) according to the procedure described for Compound 8.2.

9.1 (2RS, 3S)-3-(N-Benzyloxycarbonylasparaginy)-amino-2-hydroxy-4-phenyl-1-(N-prolylisoleucylphenylalanine methyl ester)-butane. (ZAsnPhe\*(CHOHCH<sub>2</sub>N)ProIlePheOMe).  
Compound 9.1 was prepared from Compound 8.2 (0.31g, 0.633mmol) by deprotection according to general procedure C, followed by the reaction with Compound 7.1 (0.254g, 0.57mmol) in DMF (7ml) as described in general procedure G. The crude product was reduced without further purification using NaBH<sub>4</sub> (54mg, 1.425mmol) as described in general procedure H. The crude product was purified by silica gel chromatography with 3% MeOH in

-15-

CHCl<sub>3</sub>.

9.2 2Rs, 3S)-3-(N-Benzoyloxycarbonylasparaginyl)-amino-2-hydroxy-4-phenyl-1-(N-prolylisoleucyl-3-[2-naphthyl]alanine methyl ester)-butane.

5 (ZAsnPhe\*(CHOHCH<sub>2</sub>N)ProIle-(2-Nap)AlaOMe). Compound 9.2 was prepared from Compound 8.4 (0.28g, 0.517mmol) by deprotection according to general procedure C, followed by the reaction with Compound 7.1 (0.208g, 0.466mmol) in DMF (6ml) as described in general procedure G. The crude  
10 product was reduced without further purification using NaBH<sub>4</sub> (44mg, 1.165mmol) as described in general procedure H. The crude product was purified by silica gel chromatography with 3% MeOH in CHCl<sub>3</sub>.

10.1 (2RS, 3S)-3-(N-2-Quinolylcarbonylasparaginyl)-amino-2-hydroxy-4-phenyl-1-(N-prolylisoleucylphenylalanine methyl ester)-butane. (QuAsnPhe\*(CHOHCH<sub>2</sub>N)ProIlePheOMe).  
15 Compound 9.1 (43.6mg, 0.054mmol) was deprotected by catalytic hydrogenation as described for Compound 2.3, using palladium hydroxide on carbon (10mg) and p-toluenesulphonic acid (10.5mg, 0.054mmol), followed by  
20 coupling with 2-quinolinecarboxylic acid (10.5mg, 0.059mmol) as follows. 2-Quinolinecarboxylic acid and HOBt (11.7mg, 0.086mmol) were dissolved in DCM (4ml) and cooled to 0°C EDCI (11.5mg) was added and the solution  
25 stirred for 30 min. The deprotected Compound 9.1 in DMF (3ml) was added, followed by NMM (0.007ml, 0.06mmol). The reaction was stirred for 10-12 hours at room temperature. The reaction mixture was diluted with DCM (20ml), washed with saturated NaHCO<sub>3</sub> (5ml), water (10ml), brine (10ml)  
30 and dried over MgSO<sub>4</sub>. the concentrated product was purified by silica gel chromatography with 3% MeOH in CHCl<sub>3</sub>.

10.2 (2RS, 3S)-3-(N-2-Quinolylcarbonylasparaginyl)-amino-2-hydroxy-4-phenyl-1-(N-prolylisoleucyl-3-[2-naphthyl]alanin methyl ester) - butane.  
35 (QuAsnPhe\*(CHOHCH<sub>2</sub>N)ProIl -(2-Nap)AlaOMe. Compound 9.2

-16-

(140mg, 0.16mmol) was deprotected by catalytic hydrogenation as described for Compound 2.3, using palladium hydroxide on carbon (40mg) and p-toluenesulphonic acid (32mg, 0.16mmol), followed by  
5 coupling with 2-quinolinecarboxylic acid (31mg, 0.18mmol) as described for Compound 10.1. The crude product was purified by silica gel chromatography with 3% MeOH in CHCl<sub>3</sub>.

#### Other Variants

10 It should be appreciated that many other peptides of this type can readily be synthesized using analogous procedures. One builds out from a core which is the ketone precursor of the amino-alcohol. The leucine  
15 variant or phenyl variant are preferred, but at R<sub>1</sub> various other naturally occurring or synthetic variant amino acid side chains (preferably low aryl or low alkyl groups) can be chosen (such as cyclohexyl methyl). Thereafter, one links a series of amino acid residues on one side of the core to build half the peptide. During these reactions,  
20 the free nitrogen can be protected. Separately, one then builds the other half of the peptide. Thereafter, one then couples the two halves together and creates the alcohol.

25 Preferably, the final product has an Asn moiety in it. Also, the N-terminal end can have the nitrogen protected (e.g. with a group such as acetyl, t-butoxycarbonyl, benzyloxycarbonyl, aminobenzoyl, benzoyl or very low alkyl (or C<sub>1</sub>-C<sub>5</sub>)). At the other end of the moiety, various groups such as OH or low alkyl, low aryl, esters  
30 or amides can be used.

Substitutions for hydrogen on the carbons on the proline ring and at the carbon linking the proline ring to the alcohol carbon are also within the scope of the

-17-

inv ntion. In an especially preferred form, an N-terminal cap contains an aryl residue. However, many other higher and lower carbon containing aryl, arylalkyl, and alkyl moieties should also work as N-terminal caps. For example, the claim 7 end terminal caps could have a nitrogen substitute for a carbon on the aryl ring, and/or the hydrogens on the rings replaced by various substitutes.

It will be appreciated that the above description deals only with the preferred embodiments of the invention. A number of other modifications and changes are intended to be within the scope of the invention. The claims should therefore be looked to in judging the full scope of the invention.

#### Inhibition

In addition to testing on live animals, inhibition potential can be tested by the ability to inhibit retroviral proteases with synthetic substrates and with a murine sarcoma virus Pr65gag in the assay of Katoh et al., 329 Nature 654-656 (1987). The inhibitory potency of each analog is preferably determined by using an assay analogous to that reported by J. Schneider et al. 54 Cell. 363 (1988). Briefly, synthetic HIV protease and the inhibitor are preincubated for 10 minutes in the buffer solution, and then a substrate, e.g. Ac-Thr-Ile-Met-Met-Gln-Arg-NH<sub>2</sub>, is added. The reaction mixture is maintained at 25°C. At fixed periods of time, the reaction is stopped by the addition of 10% TFA, and the formation of product monitored by analysis by HPLC. Examples of claimed compounds (final form) have been tested and shown IC<sub>50</sub> values of 1nM or smaller.


Industrial Applicability

5       The present invention provides a means to inhibit the  
ability of HIV protease to act. This should permit  
further understanding as to the mechanism of the enzyme  
and thus the virus. It also should provide potential  
drugs.

Claims

We claim:

1. A peptide having the moiety:



5

where  $R_1$  is selected from a group consisting of isobutyl, benzyl, cyclohexylmethyl, and other arylalkyl or alkyl moieties with less than twelve carbons;

10 where  $R_2$  and  $R_3$  each has at least one amino acid residue; and

where at least one of  $R_2$  or  $R_3$  has at least two amino acid residues.

2. The peptide of claim 1, wherein  $R_1$  is a side chain from a naturally occurring amino acid.

3. The peptide of claim 2, wherein  $R_2$  has a residue of asparagine.


4. The peptide of claim 3, wherein opposite ends of the peptide both have protecting groups.

5. The peptide of claim 4, wherein a 2-aminobenzoic acid protecting moiety is one of the protecting groups.



6. The peptid of claim 1, wherein R<sub>2</sub> is also linked to a moiety:


5




7. The peptide of claim 6, wherein, the aryl residue is selected from the group consisting of:



and



1/7

**SUBSTITUTE SHEET**




FIG. 2






FIG. 6




SUBSTITUTE SHEET


3/7



3.1



3.2




3.3

FIG. 3

SUBSTITUTE SHEET

FIG. 4



SUBSTITUTE SHEET






FIG. 5



SUBSTITUTE SHEET




FIG. 7




FIG. 8

SUBSTITUTE SHEET

FIG. 9







FIG. 10





# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 15 FEB 2000

Applicant's or agent's file reference 609.1PC	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US98/25964	International filing date (day/month/year) 08 DECEMBER 1998	Priority date (day/month/year) 08 DECEMBER 1997
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant THE SCRIPPS RESEARCH INSTITUTE		

- This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
- This REPORT consists of a total of 5 sheets.  
☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).  
These annexes consist of a total of 0 sheets.

- This report contains indications relating to the following items:

- ☒ Basis of the report
- ☐ Priority
- ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- ☐ Lack of unity of invention
- ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Certain documents cited
- ☐ Certain defects in the international application
- ☒ Certain observations on the international application

Date of submission of the demand 07 JULY 1999	Date of completion of this report 20 JANUARY 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer JEFFREY E. RUSSEL
Facsimil No. (703) 305-3230	Telephone No. (703) 308-0196

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/25964

## I. Basis of the report

1. This report has been drawn on the basis of (Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments):

☒ the international application as originally filed.

☒ the description, pages 1-68, as originally filed.

pages NONE, filed with the demand.

pages NONE, filed with the letter of \_\_\_\_\_.

pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

☒ the claims, Nos. 1-5, as originally filed.

Nos. NONE, as amended under Article 19.

Nos. NONE, filed with the demand.

Nos. NONE, filed with the letter of \_\_\_\_\_.

Nos. \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

☒ the drawings, sheets/fig 1-16, as originally filed.

sheets/fig NONE, filed with the demand.

sheets/fig NONE, filed with the letter of \_\_\_\_\_.

sheets/fig \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

2. The amendments have resulted in the cancellation of:

☒ the description, pages NONE.

☒ the claims, Nos. NONE.

☒ the drawings, sheets/fig NONE.

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/25964

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. STATEMENT**

Novelty (N)	Claims <u>1</u>	YES
	Claims <u>2-5</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-5</u>	NO
Industrial Applicability (IA)	Claims <u>1-5</u>	YES
	Claims <u>NONE</u>	NO

**2. CITATIONS AND EXPLANATIONS**

Claim 1 lacks an inventive step under PCT Article 33(3) as being obvious over Japan Energy Corporation Tokyo-To. Japan Energy Corporation Tokyo-To teaches an HIV-protease inhibitor at column 3, lines 25-32, and page 10, lines 1-19, which differs from Applicant's claimed protease inhibitors in that Japan Energy Corporation Tokyo-To, for the compound of page 10, does not specifically teach X being methylene, R<sub>21</sub> and R<sub>22</sub> being H, and R<sub>3</sub> being t-butyl, although these possibilities are embraced by the generic formula at page 3. It would have been obvious to one of ordinary skill in the art at the time Applicant's invention was made to form a compound according to Japan Energy Corporation Tokyo-To in which X is methylene, R<sub>21</sub> and R<sub>22</sub> are H, and R<sub>3</sub> is t-butyl, because these possibilities are embraced by the generic formula, because the choice of X being methylene and R<sub>21</sub> and R<sub>22</sub> being H results in the presence of a conventional proline residue, because the choice of R<sub>3</sub> being t-butyl is the choice of homologous small alkyl groups, and because the resulting compound has only the expected protease inhibitory activity.

Claim 2 lacks novelty under PCT Article 33(2) as being anticipated by Abbott Laboratories. Abbott Laboratories at claims 1 and 2 teaches a protease inhibitor which has the same structure as the compound recited in Applicant's claim 2.

Claim 2 lacks an inventive step under PCT Article 33(3) as being obvious over Baker et al. Baker et al teach an HIV-protease inhibitor at column 1, lines 53-64 and column 2, lines 1-17, which differs from Applicant's claimed protease inhibitors in that Baker et al, for the compound of column 2, does not specifically teach n=0, R<sub>2</sub> and R<sub>2a</sub> being carbobenzoxy, and R<sub>1</sub> being the sidechain for valine, although these possibilities are embraced by the generic formula at claim 1. It would have been obvious to one of ordinary skill in the art at the time Applicant's invention was made to form a compound according to Baker et al in which n=0, R<sub>2</sub> and R<sub>2a</sub> are carbobenzoxy, and R<sub>1</sub> is the sidechain for valine, because these possibilities are embraced by the generic formula, because n=0 is one of only two possibilities for n and is the possibility present in the more (Continued on Supplemental Sheet.)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/25964

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claim 1 is objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because the claim is indefinite for the following reason(s): At claim 1, line 23, the alternative to the phrase "are either a single combined oxygen forming a carbonyl group" is not recited.

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/25964

## Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

## CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(6): A61K 31/045, 31/13, 31/135, 31/165, 31/38, 31/405, 31/47, 31/505; C07C 205/02, 211/09, 215/18; C07D 207/16, 217/16, 217/26, 277/24, 277/28; C07K 5/062, 5/065 and US Cl.: 514/18, 19, 307, 365, 423, 483, 487, 488, 489, 654, 667, 669; 530/330; 546/146; 548/204, 537; 560/21, 22, 156; 564/374, 381, 503, 507

## V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):

preferred embodiment at column 2, formula 3, because carbobenzoxy is a conventional N-blocking group, because the choice of R<sub>1</sub> being the sidechain for valine is the choice for homologous small alkyl groups and is the possibility present in the more preferred embodiment at column 2, formula 3, and because the resulting compound has only the expected protease inhibitory activity.

Claim 2 lacks novelty under PCT Article 33(2) as being anticipated by Dreyer et al. Dreyer et al at page 941, Table II, teaches protease inhibitors which have the same structure as the compound recited in Applicant's claim 2.

Claim 2 lacks an inventive step under PCT Article 33(3) as being obvious over Kempf et al. Kempf et al teach an HIV-protease inhibitor at column 2, line 39 - column 6, line 50, and at claim 4 which differs from Applicant's claimed protease inhibitors in that Kempf et al, for the compound of claim 4, has a heterocyclic group rather than a phenyl group at R<sub>7</sub>, although this possibility is embraced by the generic formula at column 4, line 67 - column 5, line 4. It would have been obvious to one of ordinary skill in the art at the time Applicant's invention was made to form a compound according to Kempf et al in which in the compound of claim 4, R<sub>7</sub> is phenyl, because this possibility is embraced by the generic formula, because carbobenzoxy is a conventional N-blocking group, and because the resulting compound has only the expected protease inhibitory activity.

Claim 3 lacks novelty under PCT Article 33(2) as being anticipated by Handa et al. Handa et al at Examples 15 and 85 teaches compounds which have the same structure as the compound recited in Applicant's claim 3.

Claim 4 lacks novelty under PCT Article 33(2) as being anticipated by Thompson et al. Thompson et al at column 2, lines 31-48, and column 7, lines 26-39 teaches protease inhibitors which have the same structure as the compound recited in Applicant's claim 4.

Claim 5 lacks novelty under PCT Article 33(2) as being anticipated by Tien et al. Tien et al at column 4, lines 1-15, teaches a protease inhibitor which has the same structure as the compound recited in Applicant's claim 5.

Claims 1-5 meet the criteria set out in PCT Article 33(4). The claimed invention would have been expected to have industrial applicability in the inhibition of protease.


----- NEW CITATIONS -----  
NONE



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 31/045, 31/13, 31/135, 31/165, 31/38, 31/405, 31/47, 38/05, C07C 205/02, 211/09, 215/18, C07D 207/16, 217/16, 217/26, 277/24, 277/28, C07K 5/062, 5/065</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/29311</b> <b>(43) International Publication Date:</b> 17 June 1999 (17.06.99)
<b>(21) International Application Number:</b> PCT/US98/25964 <b>(22) International Filing Date:</b> 8 December 1998 (08.12.98) <b>(30) Priority Data:</b> 60/067,959 8 December 1997 (08.12.97) US <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 60/067,959 (CIP) Filed on 8 December 1997 (08.12.97) <b>(71) Applicant (for all designated States except US):</b> THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LEE, Taekyu [CA/US]; 5510 Limeric Circle, Apt. 44, Wilmington, DE 19808 (US). WONG, Chi-Huey [US/US]; P.O. Box 8154, Rancho Santa Fe, CA 92067 (US). ELDER, John, H. [US/US]; P.O. Box 7002, Rancho Santa Fe, CA 92067 (US).	<b>(74) Agents:</b> LEWIS, Donald, G. et al.; The Scripps Research Institute, 10550 North Torrey Pines Road, TPC-8, La Jolla, CA 92037 (US). <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	

**(54) Title:** HIV/FIV PROTEASE INHIBITORS HAVING A SMALL P3 RESIDUE

**(57) Abstract**

With the help of X-ray structural analyses of drug-resistant HIV proteases and molecular modeling, a new type of inhibitor with a small P3 residue has been developed. These inhibitors are effective against HIV and its drug-resistant mutants, as well as FIV. Modification of existing HIV protease inhibitors by reducing the size of the P3 residue has the same effect. This finding provides a new strategy for the development of HIV protease inhibitors effective against the wild type and drug-resistant mutants and further supports that FIV protease is a useful model for drug-resistant HIV proteases, which often are developed through reduction in size of the binding region for the P3 group or the combined P3 and P1 groups.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/25964

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 751 145 A2 (JAPAN ENERGY CORPORATION TOKYO-TO) 02 January 1997 (02/01/97), page 3, lines 25-32, page 10, lines 1-19.	1
X	WO 93/23361 A1 (ABBOTT LABORATORIES) 25 November 1993 (25/11/93), claims 1 and 2.	2
X	US 5,541,321 A (BAKER ET AL) 30 July 1996 (30/07/96), column 1, lines 53-64, column 2, lines 1-17.	2
X	DREYER et al. A Symmetric Inhibitor Binds HIV-1 Protease Asymmetrically. Biochemistry. 1993, Volume 32, Number 3, pages 937-947, especially page 941, Table II.	2

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
09 FEBRUARY 1999Date of mailing of the international search report  
25 FEB 1999Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JEFFREY E. RUSSEL

Telephone No. (703) 308-0196



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/25964

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,354,866 A (KEMPF ET AL) 11 October 1994 (11/10/94), column 2, line 39 - column 6, line 50, column 6, line 67 - column 7, line 3.	2
X	US 5,157,041 A (HANDA ET AL) 20 October 1992 (20/10/92), abstract, Examples 15, 85.	3
A	US 5,552,405 A (GORYS ET AL) 03 September 1996 (03/09/96), abstract.	3
X,P	US 5,733,906 A (JUNGHEIM ET AL) 31 March 1998 (31/03/98), column 2, line 17 - column 3, line 28, column 9, lines 17-40.	3, 4
X	US 5,502,060 A (THOMPSON ET AL) 26 March 1996 (26/03/96), column 2, lines 31-48, column 7, lines 26-39.	4
X	US 5,567,823 A (TIEN ET AL) 22 October 1996 (22/10/96), column 4, lines 1-15.	5

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/25964

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 31/045, 31/13, 31/135, 31/165, 31/38, 31/405, 31/47, 38/05; C07C 205/02, 211/09, 215/18; C07D 207/16, 217/16, 217/26, 277/24, 277/28; C07K 5/062, 5/065

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

514/18, 19, 307, 365, 423, 483, 487, 488, 489, 654, 667, 669; 530/330; 546/146; 548/204, 537; 560/21, 22, 156; 564/374, 381, 503, 507

## B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

514/18, 19, 307, 365, 423, 483, 487, 488, 489, 654, 667, 669; 530/330, 331; 546/146; 548/204, 537; 560/21, 22, 156; 564/374, 381, 503, 507

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

## APS, CHEMICAL ABSTRACTS

search terms: hiv, fiv, protease, proteinase, inhibit, carbobenzoxy, thiazol, proline, isoquinoline, structures of claims 1-5